Osborne Clarke has advised the investors Tech Vision Fonds, Segulah Medical Acceleration, XGEN Venture and Gehrenberg on their (renewed) investment in the medtech start-up Protembis GmbH.
Protembis GmbH from Aachen was founded in 2013 by Karl von Mangoldt and Conrad Rasmus and specialises in cardiovascular medical devices. Its ProtEmbo® Cerebral Protection System protects the brain from embolic material during transcatheter aortic valve implantation and is thus intended to reduce the patient's risk of stroke undergoing heart valve replacement.
The successfully completed EUR 30 million Series B financing round provides the company with additional capital to advance recruitment for their PROTEMBO Investigational Device Exemption (IDE) pivotal trial. A European consortium of VC investors led the round, including Segulah Medical Acceleration from Sweden, XGEN Venture from Italy and Tech Vision Fonds from Germany. Other investors include Coparion, several large family offices, angel investors and a multinational medical technology group.
The Osborne Clarke team, which advised Tech Vision Fonds, Segulah Medical Acceleration, XGEN Venture and Gehrenberg under the lead of Dr Jana Bertus and Dr Benjamin Monheim (responsible Partner) (both Corporate / VC), consisted of Thomas Schnabel, Moritz Windheuser, Maria Bibik, Sarah Gräfer (all Real Estate), Dr Tim Reinhard, Larissa Mößmer (both IP), Carsten Dau, Dennis Obermüller (both Commercial), Dr Marc Störing, Neil Simon-Weaver (both Data Protection) and Sonja Riedemann (Employment).
Corporate communications and press contacts
Connect with one of our experts
